4Bernell P,Ohm L.Promising activity of gemcitabine in refractory high-grade non Hodgkin's Lymphoma[J].Br J Haematol,1998,101(1):203-204.
5Fossa A,Santoro A,Hiddemann W,et al.Gemcitabine as a singal agent in the treatment of relapsed or refractory aggressive non-Hodgkin's Lymphoma[J].J Clin Oncol,1999,17(12):3786-3792.
3Manegold C, Bergmann B, Chemaissani A, et al. Singleagent gemcitabine versus cisplatin-etoposide: Early results of a randomizead phase Ⅱ study in locally advanced or metastatic nonsmall cell lung cancer[J]. Ann Oncol, 1997,8(6):525.
4Peng R P, Chen Y M, Ming-Liu J, et al. Gwmcitabine versus the combination of cispatin and etoposide in patients with inoperable non-small cell lung cancer in a phase Ⅱ randomized study [J]. J Clin Oncol, 1997, 15(5):2097.
5Raymond E, Chaney S, Taamma A, et al. Oxalipatin:A review of preclinical and clinical studies[J]. Ann Oncol, 1998, 9 (7):1053-1071.
6Monnel I, Brienza S, Hugret F, et al. Phase Ⅱ study of oxaliplatin in poor-prognosis non-small cell lung cancer [J] . Europ J of Cancer, 1998, 34(7) :1124-1127.
7Faivre S, Le Chervalier T, Monnerat C, et al. Phase Ⅰ - Ⅱ and phanrmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian Carcinoma[J]. Ann Oncol, 2002, 13(9): 1479- 1489
8Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 1994, 84: 1361-1392.
9Specht L, Gray RJ, Clarke MJ, et al. Influence of more extensive radiotherapy, and adjuvant chemotherapy on long-term outcome of early stage Hodgkin′s disease: a meta-analysis of 23 randomized trials involving 3 888 patients. international Hodgkin′s disease Collaborative Group. J Clin Oncol,1998,16:830-843.
10Duggan D, Petroni G, Johnson J, et al. MOPP/ABV versus ABVD for advanced Hodgkin′s disease - a preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC). Proc Am Soc Clin Oncol, 1997,16:13a.
